CCG 1423, Rho pathway-mediated signaling inhibitor (ab229181)
Key features and details
- Specific inhibitor of Rho pathway-mediated signaling and activation SRF transcription
- CAS Number: 285986-88-1
- Purity: > 98%
- Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
CCG 1423, Rho pathway-mediated signaling inhibitor -
Description
Specific inhibitor of Rho pathway-mediated signaling and activation SRF transcription -
Alternative names
- N-[2-[(4-Chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)benzamide
-
Biological description
Specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. Displays activity in several in vitro cancer cell functional assays. Potently (<1 mumol/L) inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells, inhibits growth of RhoC-overexpressing melanoma lines at nanomolar concentrations. Selectively stimulates apoptosis of the metastasis-prone, RhoC-overexpressing melanoma cell lines. Acts at or downstream of MLK1 and upstream of SRF. Blocks MLK1 nuclear localization.
-
Purity
> 98% -
General notes
This product is manufactured by BioVision, an Abcam company and was previously called 9434 CCG-1423. 9434-25 is the same size as the 25 mg size of ab229181.
-
CAS Number
285986-88-1
Properties
-
Chemical name
N-[2-[(4-Chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)benzamide -
Molecular weight
454.75 -
Molecular formula
C18H13ClF6N2O3 -
PubChem identifier
2726015 -
Storage instructions
Shipped at 4°C. Store at -20°C long term. Store In the Dark. Store under desiccating conditions. -
Solubility overview
Soluble in DMSO to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CC(C(=O)NC1=CC=C(C=C1)Cl)ONC(=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F -
Source
Synthetic
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (5)
ab229181 has been referenced in 5 publications.
- Kikuchi K et al. Rho signaling inhibitor, CCG-1423, inhibits axonal elongation and dendritic complexity of rat cortical neurons. Biochem Biophys Res Commun 492:474-479 (2017). PubMed: 28830810
- Hayashi K et al. RPEL proteins are the molecular targets for CCG-1423, an inhibitor of Rho signaling. PLoS One 9:e89016 (2014). PubMed: 24558465
- Bell JL et al. Design and synthesis of tag-free photoprobes for the identification of the molecular target for CCG-1423, a novel inhibitor of the Rho/MKL1/SRF signaling pathway. Beilstein J Org Chem 9:966-73 (2013). PubMed: 23766813
- Jin W et al. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest 121:918-29 (2011). PubMed: 21393865
- Evelyn CR et al. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther 6:2249-60 (2007). PubMed: 17699722